A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Inclusion Criteria:

• Diagnosed with moderate to severe chronic plaque psoriasis for at least 6 monthsbefore Baseline (Week 0).
• Participant must have been on labeled secukinumab or ixekizumab treatment for at least 6 months and are experiencing suboptimal response at time of Screening and Baselinevisits.
• Participant must have a Body Surface Area (BSA) 3%- <10% and Static Physician GlobalAssessment (sPGA) 2/3
• Participant must be eligible for continued biologic therapy as assessed by theinvestigator.

Exclusion Criteria:

• History of erythrodermic psoriasis, generalized or localized pustular psoriasis,medication-induced or medication-exacerbated psoriasis, or new onset guttatepsoriasis, psoriatic arthritis.
• Participant with active skin disease other than plaque psoriasis that could interferewith the assessment of plaque psoriasis.
• History of any documented active or suspected malignancy or history of any malignancywithin the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
• History of major surgery within 12 weeks prior to Baseline or planned to be performedduring the conduct of the trial as assessed by the investigator.
• Participant with exposure to risankizumab or any IL-23 inhibitors.